Work

Focus

Year: 2011

Type: article

Abstract: Efforts to understand hepatocellular carcinoma (HCC) are at a fever pitch because of the epidemic incidence of the disease and the paradigm-shifting SHARP trial [1], which established this neoplasm as a tractable target for molecular therapies. As a result, identifying new molecular targets and improving the diagnosis of early disease are major points of attack, and two articles from this month’s issue address these important topics.

Source: Journal of Hepatology

DOI: 10.1016/j.jhep.2011.08.009

Author: Scott L. Friedman

Institution: Icahn School of Medicine at Mount Sinai

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,500